Troy E Barger
Overview
Explore the profile of Troy E Barger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kroenke M, Barger T, Hu J, Miller M, Kalenian K, He L, et al.
Front Immunol
. 2021 Dec;
12:782788.
PMID: 34970265
AMG 966 is a bi-specific, heteroimmunoglobulin molecule that binds both tumor necrosis factor alpha (TNFα) and TNF-like ligand 1A (TL1A). In a first-in-human clinical study in healthy volunteers, AMG 966...
2.
Bowers C, Mytych D, Lawrence T, Wang K, Barger T, Eisen M, et al.
Blood Adv
. 2021 Oct;
5(23):4969-4979.
PMID: 34638135
Development of first-generation thrombopoietins (TPOs) was halted due to antibodies that neutralized endogenous TPO, causing protracted thrombocytopenia in some patients. The second-generation TPO receptor agonist romiplostim, having no homology to...
3.
Mytych D, Park J, Kim J, Barger T, Boshier A, Jawa V, et al.
Br J Haematol
. 2020 Apr;
190(6):923-932.
PMID: 32311075
Antibodies to first-generation recombinant thrombopoietin (TPO) neutralized endogenous TPO and caused thrombocytopenia in some healthy subjects and chemotherapy patients. The second-generation TPO receptor agonist romiplostim, having no sequence homology to...
4.
Andrews D, Hamadeh H, He Y, Boren B, Turk J, Boyce R, et al.
Toxicol Pathol
. 2013 May;
42(3):540-54.
PMID: 23674392
We previously reported an increased incidence of thrombotic toxicities in Sprague-Dawley rats administered the highest dose level of a hyperglycosylated analog of recombinant human erythropoietin (AMG 114) for 1 month...
5.
Andrews D, Boren B, Turk J, Boyce R, He Y, Hamadeh H, et al.
Toxicol Pathol
. 2013 May;
42(3):524-39.
PMID: 23674391
We recently reported results that erythropoiesis-stimulating agent (ESA)-related thrombotic toxicities in preclinical species were not solely dependent on a high hematocrit (HCT) but also associated with increased ESA dose level,...
6.
Barger T, Wrona D, Goletz T, Mytych D
Nephrol Dial Transplant
. 2012 Nov;
27(10):3892-9.
PMID: 23114907
Background: The antibody characteristics in erythropoiesis-stimulating agent (ESA)-treated patients who develop antibody-mediated pure red cell aplasia (PRCA; amPRCA) can be described as high-affinity, neutralizing anti-ESA antibodies with a mixed immunoglobulin...
7.
Mytych D, Barger T, King C, Grauer S, Haldankar R, Hsu E, et al.
J Immunol Methods
. 2012 May;
382(1-2):129-41.
PMID: 22634015
Recombinant human erythropoietin (EPO) has been used therapeutically for more than two decades in the treatment of anemia. Although EPO is generally well tolerated, in rare cases, patients have developed...
8.
Barger T, Kuck A, Chirmule N, Swanson S, Mytych D
Nephrol Dial Transplant
. 2011 May;
27(2):688-93.
PMID: 21602184
Background: The immunological methods for detecting antibodies to erythropoiesis-stimulating agents (ESAs) differ in assay sensitivity. However, this parameter, routinely determined in clinical assays using a high-affinity non-human polyclonal antibody, gives...
9.
Barger T, Zhou L, Hale M, Moxness M, Swanson S, Chirmule N
AAPS J
. 2009 Dec;
12(1):79-86.
PMID: 20012239
The immunogenicity immunoassay validation process ensures development of a robust, reproducible method. However, no matter how well developed, validated, and maintained a method is, in the course of running a...